首页> 外文期刊>Diagnostics >Hepatocellular Carcinoma, Fibrolamellar Variant: Diagnostic Pathologic Criteria and Molecular Pathology Update. A Primer
【24h】

Hepatocellular Carcinoma, Fibrolamellar Variant: Diagnostic Pathologic Criteria and Molecular Pathology Update. A Primer

机译:肝细胞癌,纤维状变种:诊断病理学标准和分子病理学更新。入门

获取原文
       

摘要

Fibrolamellar hepatocellular carcinoma (FL-HCC) is generally a fairly rare event in routine pathology practice. This variant of hepatocellular carcinoma (HCC) is peculiarly intriguing and,in addition, poorly understood. Young people or children are often the target individuals with this type of cancer. Previously, I highlighted some pathology aspects of FL-HCC, but in this review, the distinctive clinico-pathologic features of FL-HCC and the diagnostic pathologic criteria of FL-HCC are fractionally reviewed and expanded upon. Further, molecular genetics update data with reference to this specific tumor are particularly highlighted as a primer for general pathologists and pediatric histopathologists. FL-HCC may present with metastases, and regional lymph nodes may be sites of metastatic spread. However, peritoneal and pulmonary metastatic foci have also been reported. To the best of our knowledge, FL-HCC was initially considered having an indolent course, but survival outcomes have recently been updated reconsidering the prognosis of this tumor. Patients seem to respond well to surgical resection, but recurrences are common. Thus, alternative therapies, such as chemotherapy and radiation, are ongoing. Overall, it seems that this aspect has not been well-studied for this variant of HCC and should be considered as target for future clinical trials. Remarkably, FL-HCC data seem to point to a liver neoplasm of uncertain origin and unveiled outcome. A functional chimeric transcript incorporating DNAJB1 and PRKACA was recently added to FL-HCC. This sensational result may give remarkable insights into the understanding of this rare disease and potentially provide the basis for its specific diagnostic marker. Detection of DNAJB1-PRKACA seems to be, indeed, a very sensitive and specific finding in supporting the diagnosis of FL-HCC. In a quite diffuse opinion, prognosis of this tumor should be reconsidered following the potentially mandatory application of new molecular biological tools.
机译:在常规病理学实践中,纤维状肝细胞癌(FL-HCC)通常是相当罕见的事件。肝细胞癌(HCC)的这种变体特别令人着迷,并且了解甚少。年轻人或儿童通常是这类癌症的目标人群。之前,我重点介绍了FL-HCC的一些病理方面,但在本综述中,对FL-HCC的独特临床病理特征和FL-HCC的诊断病理学标准进行了部分回顾和扩展。此外,针对该特定肿瘤的分子遗传学更新数据作为普通病理学家和小儿组织病理学家的入门特别突出。 FL-HCC可能伴有转移,局部淋巴结可能是转移扩散的部位。但是,也有腹膜和肺转移灶。据我们所知,FL-HCC最初被认为具有缓慢的病程,但最近已经更新了生存结果,重新考虑了该肿瘤的预后。病人对手术切除的反应似乎很好,但是复发很常见。因此,正在进行替代疗法,例如化学疗法和放射疗法。总体而言,似乎对于HCC的这种变体尚未对此方面进行充分研究,应将其视为未来临床试验的目标。值得注意的是,FL-HCC数据似乎指向来源不确定的肝肿瘤,并显示了结果。掺入DNAJB1和PRKACA的功能性嵌合转录物最近被添加到FL-HCC中。这一轰动的结果可能会为了解这种罕见疾病提供非凡的见解,并可能为其特定的诊断标志物提供基础。实际上,DNAJB1-PRKACA的检测似乎是支持FL-HCC诊断的非常敏感和特异性的发现。在一个非常分散的观点中,应在潜在的强制性应用新的分子生物学工具后重新考虑该肿瘤的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号